urosphere
News & events
Acquisition of Urolead company.
Urosphere is pleased to announce its acquisition of Urolead company.
Urosphere will be present at the International Continence Society 2017
Urosphere will present an oral communication at ICS (Florence, 12-15 september 2017)
Urosphere will be present at the European Association of Urology congress 2017
Urosphere will present two posters at the 32st annual EAU congress (24-28 March 2017).
Urosphere presented two posters at ERA-EDTA congress
Urosphere presented two posters in collaboration with Solid Drug Development at the 53rd annual ERA-EDTA congress: Effect of JNK inhibitor in a rat model of renal ischemia-reperfusion injury (link) Effects of JNK inhibitor on puromycin aminonucleoside-induced nephropathy in rats (link) Please click on links next to the posters titles to see them.
Urosphere will be present at the European Association of Urology congress 2016
UROSPHERE will present two posters at the 31st annual EAU congress (13 March 2016 at 12:45 PM, room 14a)
Urosphere will attend the toulouse oncoweek, to be held in toulouse, france, february 03-05, 2016.
We will have an oral communication on “Optical imaging in preclinical tumour models: helpful or pitfall?”
Urosphere and Ambiotis sign a strategic collaboration agreement
Urosphere and Ambiotis another Contract Research Organization, based in Toulouse, France announce a strategic partnership to broaden and strenghten their respective activities. Under this agreement, the two companies intend to combine their skills to offer an even more integrated approach to their customers. UROSPHERE will indeed bring its expertise in building physiological and pathological animal models within the uro-genital, gastro-intestinal and oncological areas while Ambiotis will offer...
Season’s Greetings and Best Wishes!
Best wishes from UROSPHERE for a great year 2016 !
UROSPHERE ANNOUNCES ISO 9001 CERTIFICATION.
Urosphere is pleased to announce another step in its commitment to the highest quality standards. Urosphere obtained the certification of its Quality Management System (QMS) ISO 9001: 2008 provided by Lloyd's Register Quality Assurance (LRQA), a world’s leading provider of certifications. “Today, we become the first CRO specialized in preclinical pharmacology in the field of urogenital pathologies. We provide to our customers an internationally recognized certification of its QMS not only for...
ORGANOCAN : UROsphere collaborative project.
Colorectal cancers and those of the urological sphere (prostate and bladder) are among the five most common cancers. A chronic inflammatory condition predisposes to the appearance of some of these cancers (colon, prostate). Today, the available experimental models poorly simulate the biological reality and function of the body, which makes it particularly difficult to develop new drugs. The objective of the Organocan 2 project is to develop cell models in 3-dimensional (organoid) of colon,...
Urosphere will be present at the European Association of Urology congress 2016
UROSPHERE will present two posters at the 31st annual EAU congress (13 March 2016 at 12:45 PM, room 14a)
Urosphere will attend the toulouse oncoweek, to be held in toulouse, france, february 03-05, 2016.
We will have an oral communication on “Optical imaging in preclinical tumour models: helpful or pitfall?”
UROsphere attended to the Association Française des Sciences et Techniques de l’Animal de Laboratoire (AFSTAL) annual meeting, Toulouse, France, from 4 to 6 June 2014.
Dr. Murielle Méen presented an oral communication on Wednesday June 4th entitled: UROsphere, experimental platform for urogenital disorders: Focus on interstitial cystitis.
UROsphere will present its latest scientific developments in preclinical sex health models at the annual meeting of the American Urological Association, to be held in Orlando, Florida, May 16-21, 2014.
Dr Julien Allard will present two moderated posters (session Sexual Function/Dysfunction/Andrology: Basic Research II, room W307) on Monday, May 19th, 08:00-10:00 AM: Poster 1: Dapoxetine inhibits erectile responses to stimulation of cavernous nerve in rats: a new hypothesis for its effects on ejaculation. Poster 2: Mice with the null leptin receptor as a translational model of type II diabetes-induced erectile dysfunction: in vivo assessment and the effect of sildenafil....
UROsphere will present scientific results at the European Association for Urology Annual Meeting, Stockholm, Sweden from 11 to 15 April 2014.
Dr Julien Allard (E-phys) will present the Poster entitled "Dapoxetine inhibits erectile responses to stimulation of cavernous nerve in rats: a new hypothesis for its effects on ejaculation" (final abstract #497). The poster will be presented at Poster Session 40 (room T1) on Sunday, 13 April 2014 from 12:15 to 13:45.
UROsphere presents scientific results at the International Continence Society (ICS) annual meeting (Barcelona, Spain, 26 – 30 August 2013).
The following scientific results will be presented : DFL 14817, a new potent and selective TRPM8 antagonist for the treatment of urinary bladder disorders.Palea S1, Guilloteau V1, Brandolini L2, Guardia M1, Rollet K1, Guerard M1, Bianchini G2, Lluel P1, Aramini A2.1. UROsphere, 2. Dompé S.p.A.Podium Session 3 - Basic Science 1: InnovationsWednesday 28th August 2013 - 11:05-12:05. Modulation of PGE2-augmented micro-contractions by the non-selective ß-adrenoceptor agonist isoprenaline in...
UROsphere will present scientific results at the International Symposium on Prostate, Androgens and Men’s Sexual Health, which will take place in Berlin, Germany from 21 to 23 June 2013.
Dr Julien Allard will present the Unmoderated Poster entitled " Mice with null leptin receptor as a translational model of type II diabetes induced erectile dysfunction: in vivo assessment and effect of sildenafil " (final abstract #38). The poster exhibition will be located in meeting room "Postdam I and II" open to all delegates on: Friday 21 June 2013 11:00-19:30 hrs Saturday 22 June 2013 08:00-19:30 hrs UROsphere's Chief Scientific Officer, Stefano Palea,...
UROsphere present scientific results at EAU 27th annual congress (Paris, France, 24-26 February 2012)
It is with pleasure that we will meet you at the booth 1N24, level 1, hall Passy. The following posters will be presented on Sunday, 26 February 2012 from 09h15 to 10h45. Effect of a selective β3-adrenergic agonist (CL-316, 243) on cystometric parameters in conscious spinal cord injured female rats. J.B. Beauval , V. Guilloteau , M. Capellini , A. Naudin , M. Guérard , P. Lluel , S. Palea , P. Rischmann , X. Gamé. Dose-dependent effect of a selective β3 adrenoreceptor agonist...
UROsphere presents scientific results at the 16th World Congress of Basic and Clinical Pharmacology (Copenhagen, Denmark, 17-23 July 2010)
The following posters will be presented: Comparison of the effects of AdTx1 and tamsulosin on the increase in intra-urethral and arterial pressures induced by phenylephrine in anesthetized male rats. Effects of duloxetine on bladder and external urethral sphincter in anesthetized female guinea-pigs with intravesical acetic acid. Stimulation of β3-adrenoceptors inhibits EFS-induced contractions of human isolated urinary bladder. Stimulation of both β2- and...
Urosphere will attend ICS annual meeting and present several scientific communications. (Rotterdam, Netherlands, August 20-24, 2007)
View the posters presented. If you wish to meet UROsphere's senior managers during ICS meeting, please contact us.
Urosphere takes parts in MAGenTA, a collaborative research project to develop innovative experimental models and clinical trials dedicated to urogenital diseases.
The MAGenTA project consists into a collaborative work between four SMEs and two academic institutions. The aim is to develop new and innovative predictive experimental models in order to provide pharmaceutical companies and academic research with better tools that should facilitate the validation of gene candidates and discovery of new molecules. MAGenTA also includes two clinical studies which will enable validation of the effectiveness of two therapeutic molecules for urogenital diseases....
Urosphere unveils its new web site
UROsphere is pleased to present its new web site that has been redesigned to offer enhanced functionality to better fit with our clients’ needs: Quick access to our assays, models and expertise A restricted area dedicated to our clients Personalized filter by disease area listing pertinent publications Subscribe to our RSS feed to receive our news updates Feel free to contact us with any questions or comments, we will be happy to assist you.
UROsphere and Vectalys selected by the SISMIP for their research programme « Discovery of new targets for prostatic pathologies»
The 3SI program for Innovation in the Health Sector is a call for innovative projects reserved to SMEs located in Midi-Pyrenees Region. This program is also supported by the Regional Board of OSEO (France's national agency for industrial innovation), the Regional Board for Research and Technology (DRRT), the Cancer-Bio-Health cluster and Midi Pyrénées Innovation (MPI). UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery...
Urosphere receives a grant from OSEO Innovation.
UROsphere announces that OSEO Innovation has awarded a grant over a 2-year period to expand its experimental research platform for early stage drug development. The funding will be used to develop innovative in vivo and in vitro models to offer a wider range of assays for genitourinary pathologies. OSEO innovation (France's national agency for industrial innovation) funds innovative, technology-oriented projects for commercialization in France and abroad.
Urosphere targets genitourinary pathologies (FR)
UROsphere cible les pathologies génitourinaires. (Gazette du Laboratoire, Mai 2007) Spécialisée sur le marché de niche des pathologies de l'appareil urinaire, cette jeune entreprise innovante toulousaine développe ses propres molécules et propose des services (études pré-cliniques) à ses clients internationaux. Article
“2007: an important year for Urosphere” (FR)
"2007 sera une année capitale pour UROsphere". (Biotech Finances, 19/02/07) En forte croissance depuis son essaimage, UROsphere doit franchir cette année un cap important. Article
Urosphere developed a new experimental model for prostate enlargment.
"Prostatic enlargment and inflamation" is a well estalished model for BPH in rats.
Urosphere joins SISMIP, a health industry association.
UROsphere s'associe au SISMIP, le groupement des industries de la santé en Midi-Pyrénées.
UROsphere continues to grow. (FR)
UROsphere en pleine croissance. (Actu Labo, 24/01/07) Article
UROsphere develops its two main activities abreast. (La Tribune)
Spécialisée dans les pathologies de l'appareil urinaire, la société toulousaine élabore ses propres médicaments. Elle propose aussi ses services aux "big pharmas" du secteur. (La Tribune, 16/01/07)